Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.59 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CBFB | Q13951 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12575545 | 0.86 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL11825400 | 0.85 | EHMT2 (0.81) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL21545797 | 0.83 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL15314312 | 0.83 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL31005452 | 0.82 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL28582259 | 0.82 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL28757007 | 0.80 | EHMT2 (0.65) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL11824315 | 0.80 | EHMT2 (0.71) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| SCHEMBL15044501 | 0.79 | EHMT2 (0.77) | EHMT2EHMT1APOBEC3GL3MBTL1POLB | |
| Ethylene Glycol SCHEMBL3505769 | 0.79 | EHMT2 (0.77) | EHMT2EHMT1APOBEC3GL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12410262-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-113039191-B | Nucleotide analogues | 奇异基因组学系统公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240010755-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. | 2024-01-11 | — | — | US | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11634508-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634508-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| EP-2217063-B1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | VIRGINIA TECH INTELL PROP (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8558019-B2 | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8558019-B2 | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | ZAHAV BIOSCIENCES LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | ZAHAV BIOSCIENCES LLC | 2011-06-16 | — | — | US | disclosed |
| WO-2009062138-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PAICS, CYTH3, CYTH2 | EHMT2 3113/4885EHMT1 3252/4885APOBEC3G 506/4885 |
| US-12410262-B2 | Peptide conjugates of cytotoxins as therapeutics | TOP1, TOP2A, TOP2B | EHMT2 2906/4885EHMT1 2376/4885APOBEC3G 824/4885 |
| US-11634508-B2 | Peptide conjugates of cytotoxins as therapeutics | TOP1, TOP2A, TOP2B | EHMT2 2906/4885EHMT1 2376/4885APOBEC3G 824/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | EHMT2 3448/4885EHMT1 3402/4885APOBEC3G 3684/4885 |
| US-20240010755-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | TOP1, TOP2A, TOP2B | EHMT2 2906/4885EHMT1 2376/4885APOBEC3G 824/4885 |
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, EGLN3 | EHMT2 1296/4885EHMT1 1630/4885APOBEC3G 3361/4885 |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | TUBB6, TUBB1, TUBB | EHMT2 4228/4885EHMT1 4017/4885APOBEC3G 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.